Home › Funds › FORBES J M & CO LLP › DNA
FORBES J M & CO LLP position in DNA
GINKGO BIOWORKS HOLDINGS INC · Health Care
FORBES J M & CO LLP reported holding 977,371 shares of DNA (GINKGO BIOWORKS HOLDINGS INC) in its Q3 2026 13F filing — a position valued at US$12.5M, representing 1.10% of its reported portfolio and ranking #29 among its reported holdings. FORBES J M & CO LLP has disclosed DNA holdings in 9 of the last 9 reported quarters, going back to Q3 2024.
Last updated: 2026-10-16 · Source: SEC EDGAR Form 13F-HR
How FORBES J M & CO LLP's DNA position evolved
FORBES J M & CO LLP first disclosed a stake in DNA in Q3 2024 at 125,000 shares (US$1.0M). The position peaked in Q3 2025 at 1,060,341 shares, worth US$15.5M. Across 9 filings, FORBES J M & CO LLP increased the stake 2 time(s), trimmed it 6 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 977,371 shares valued at US$12.5M — a reduction of -22,540 shares quarter over quarter.. Notable position changes include a 461% increase in Q4 2024 (shares fell 42% over the following quarter), a 56% increase in Q1 2025 (shares rose 97% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2024 | 125.00K | $1.02M | New |
| Q4 2024 | 701.73K | $6.89M | Add |
| Q1 2025 | 1.09M | $6.24M | Add |
| Q2 2025 | 1.08M | $12.12M | Reduce |
| Q3 2025 | 1.06M | $15.46M | Reduce |
| Q4 2025 | 1.04M | $8.65M | Reduce |
| Q1 2026 | 1.03M | $6.30M | Reduce |
| Q2 2026 | 999.91K | $9.91M | Reduce |
| Q3 2026 | 977.37K | $12.54M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DNA and 13F data
DNA (GINKGO BIOWORKS HOLDINGS INC) is a Health Care company. 32 other funds we track also report a position in DNA — the largest reported positions include Anchorage Capital Group, L.L.C. (US$17.3M), SB INVESTMENT ADVISERS (UK) LTD (US$6.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DNA
- Anchorage Capital Group, L.L.C. 1.75M sh · $17.31M · Q2 2026
- SB INVESTMENT ADVISERS (UK) LTD 610.73K sh · $6.05M · Q2 2026
More on FORBES J M & CO LLP
FAQ
How long has FORBES J M & CO LLP held DNA?
FORBES J M & CO LLP has disclosed DNA holdings in 9 of the last 9 reported quarters, going back to Q3 2024.
What is FORBES J M & CO LLP's current position in DNA?
As of Q3 2026, FORBES J M & CO LLP holds 977.37K shares of DNA (GINKGO BIOWORKS HOLDINGS INC), valued at $12.54M, representing 1.10% of its reported portfolio and ranking #29.
Has FORBES J M & CO LLP been buying or selling DNA?
In the latest 13F filing (Q3 2026), FORBES J M & CO LLP reduced its position in DNA. The position peaked in Q3 2025 at 1.06M shares.
Which other funds hold DNA?
Other major institutional holders of DNA include Anchorage Capital Group, L.L.C., SB INVESTMENT ADVISERS (UK) LTD, among 32 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.